Account
Insider Insights
01.02.2022
Proposals for reforming public and private health

The report looks at four possible scenarios including most notably the creation of a “grande Sécu...

Read more
Insider Insights
01.02.2022
Orphan drugs not included in reference price order

The Court has annulled the inclusion of the orphan drug Onivyde (irinotecan) in the reference price ...

Read more
Insider Insights
01.02.2022
Proposals aimed at building together our future

The association proposes concentrating efforts around four primary objectives.

Read more
Insider Insights
01.02.2022
Orphan drugs undergo early benefit assessment

According to the Institute for Quality and Efficiency in Health Care orphan drugs should undergo ear...

Read more
Insider Insights
01.02.2022
Germany completes early benefit assessments

In addition to new cancer drugs, the G-BA also evaluated the first antiviral drug to treat COVID-19 ...

Read more
Insider Insights
01.02.2022
Early access granted to Xevudy

Notably, the early access scheme was reformed with effect from 1st July 2021.

Read more
Insider Insights
01.02.2022
NICEs new methods and processes manual

The National Institute for Health and Care Excellence (NICE) on 31st January 2022 published its new ...

Read more
Insider Insights
01.02.2022
Prescribing controls on new medicines

The Ministry of Health reports that 65.1% of medicines admitted to reimbursement in 2021 were subjec...

Read more
Insider Insights
09.06.2020
Innovation passport awarded to hypertension treatm

The passport is the entry point to the Innovative Licensing and Access Pathway (ILAP) which aims to ...

Read more
Insider Insights
22.02.2020
Recommendations for market access reforms

This resolution includes proposed reforms to the market access (including pricing) landscape designe...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.